CR9322A - Metodos para control del intervalo qt - Google Patents

Metodos para control del intervalo qt

Info

Publication number
CR9322A
CR9322A CR9322A CR9322A CR9322A CR 9322 A CR9322 A CR 9322A CR 9322 A CR9322 A CR 9322A CR 9322 A CR9322 A CR 9322A CR 9322 A CR9322 A CR 9322A
Authority
CR
Costa Rica
Prior art keywords
control methods
interval control
subject
formula
group
Prior art date
Application number
CR9322A
Other languages
English (en)
Inventor
Chien Shuchean
Novak Gerald
Truyen Luc
Yuen Eric
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36147919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9322(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR9322A publication Critical patent/CR9322A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Esta invencion se relaciona con metodos para controlar la duracion de la despolarizacion y repolarizacion del ventriculo cardiaco y por lo tanto del intervalo QT, de manera terapeuticamente utiles en un sujeto, que comprende administrar al sujeto en necesidad del mismo una cantidad terapeuticamente eficaz de un compuesto que se selecciona del grupo que consiste de la formula (I) y la formula (II) o una sal o ester farmaceuticamente aceptable del mismo; en donde fenilo esta sustituido en X con uno a cinco atomos de halogeno que se seleccionan del grupo que consiste de fluor, cloro, bromo y yodo.
CR9322A 2005-01-20 2007-08-17 Metodos para control del intervalo qt CR9322A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64544705P 2005-01-20 2005-01-20

Publications (1)

Publication Number Publication Date
CR9322A true CR9322A (es) 2008-09-09

Family

ID=36147919

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9322A CR9322A (es) 2005-01-20 2007-08-17 Metodos para control del intervalo qt

Country Status (18)

Country Link
US (1) US7846968B2 (es)
EP (1) EP1850841A1 (es)
JP (1) JP2008528489A (es)
KR (1) KR20080025034A (es)
CN (1) CN101146527A (es)
AR (1) AR052885A1 (es)
AU (1) AU2006206778A1 (es)
BR (1) BRPI0606484A2 (es)
CA (1) CA2595599A1 (es)
CR (1) CR9322A (es)
EA (1) EA200701536A1 (es)
IL (1) IL184730A0 (es)
MX (1) MX2007008845A (es)
NO (1) NO20074175L (es)
NZ (1) NZ556497A (es)
TW (1) TW200637540A (es)
WO (1) WO2006078524A1 (es)
ZA (1) ZA200706916B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4719890B2 (ja) * 2006-11-09 2011-07-06 国立大学法人三重大学 トルサード・ド・ポアンツ型心室頻拍を呈するゼブラフィッシュ
CZ2007376A3 (cs) * 2007-05-30 2008-12-10 Ústav prístrojové techniky AV CR, v.v.i. Zpusob analýzy ventrikulární repolarizace
JP2010538728A (ja) * 2007-09-12 2010-12-16 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ アラーム及び動向付け機能を有するｑｔ間隔監視システム
US8019406B2 (en) * 2008-03-10 2011-09-13 Biotronik Crm Patent Ag Apparatus and method to assess the risk of R-on-T event
FR2953410B1 (fr) * 2009-12-09 2012-02-24 Univ Claude Bernard Lyon Compositions antivirales pharmaceutiques ou veterinaires
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
JP6954582B2 (ja) * 2016-12-22 2021-10-27 国立大学法人滋賀医科大学 医薬組成物
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US12117453B2 (en) 2018-12-07 2024-10-15 Washington University Predicting patient response to sodium channel blockers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
CZ2003445A3 (cs) * 2000-07-21 2004-08-18 Ortho@Mcneilápharmaceuticalźáinc Karbamátové sloučeniny pro prevenci nebo léčbu neuropatické bolesti a bolesti asociované s histaminovou a migrenózní bolestí hlavy
MXPA03007720A (es) * 2001-02-27 2004-11-12 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o el tratamiento de transtornos de ansiedad.

Also Published As

Publication number Publication date
MX2007008845A (es) 2007-11-08
AR052885A1 (es) 2007-04-11
NZ556497A (en) 2011-03-31
TW200637540A (en) 2006-11-01
EA200701536A1 (ru) 2008-02-28
ZA200706916B (en) 2009-04-29
CN101146527A (zh) 2008-03-19
US20070010578A1 (en) 2007-01-11
AU2006206778A1 (en) 2006-07-27
JP2008528489A (ja) 2008-07-31
WO2006078524A1 (en) 2006-07-27
CA2595599A1 (en) 2006-07-27
BRPI0606484A2 (pt) 2009-06-30
NO20074175L (no) 2007-10-11
US7846968B2 (en) 2010-12-07
EP1850841A1 (en) 2007-11-07
KR20080025034A (ko) 2008-03-19
IL184730A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
CR9322A (es) Metodos para control del intervalo qt
ECSP088179A (es) Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos
PE20201146A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
ECSP088172A (es) Metodos para tratar la epileptogenesis
AR062980A1 (es) Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida
TW200612911A (en) Compounds for the treatment of inflammatory disorders
CY1111363T1 (el) Τρικυκλικος ανταγωνιστης υποδοχεων θρομβινης
GT200600055A (es) Combinación de compuestos organicos
TW200616620A (en) Compounds for the treatment of inflammatory disorders
IL311873A (en) Combination therapy for treating malignancies
CY1114266T1 (el) Ανταγωνιστης υποδοχεα της αγγειοτενσινης ιι για τη θεραπευτικη αγωγη συστημικων νοσων σε γατες
EP3915566A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE, CONTAINING TAURODEOXYCHOLIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS THE ACTIVE INGREDIENT
ECSP11011030A (es) Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional.
MA32785B1 (fr) Procede de traitement ou de prevention de thrombose a l'aide d'etexilate de dabigatran ou d'un sel de celui-ci avec une efficacite accrue par rapport a une therapie classique par warfarine
NO20072934L (no) Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt
TNSN07447A1 (en) Treatment of liver diseases in which iron plays a role in pathogenesis
DK2078022T3 (da) Spirobenzazepiner anvendt som vasopressinantagonister
PE20230680A1 (es) Inhibidores de il4i1 y metodos de uso
PA8426801A1 (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
ECSP077395A (es) Compuesto de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
CR7854A (es) Dihidrofenantridinosulfonamidas sustituidas
AR127507A1 (es) Agonistas de rxfp1
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
NZ780304A (en) Uses of phosphodiesterase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)